Published in Proteomics on August 01, 2005
Extracellular microRNA: a new source of biomarkers. Mutat Res (2011) 2.55
Human body fluid proteome analysis. Proteomics (2006) 2.39
Comparing the MicroRNA spectrum between serum and plasma. PLoS One (2012) 2.34
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
Antibody orientation at bacterial surfaces is related to invasive infection. J Exp Med (2012) 2.30
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Discovery and validation of graft-versus-host disease biomarkers. Blood (2012) 1.67
Interferences from blood collection tube components on clinical chemistry assays. Biochem Med (Zagreb) (2014) 1.39
LC-MS-based metabolomics. Mol Biosyst (2011) 1.36
Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics (2010) 1.27
Before you analyze a human specimen, think quality, variability, and bias. Anal Chem (2010) 1.19
SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics (2012) 1.11
Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement (2014) 1.06
A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. J Biomed Biotechnol (2009) 1.05
Proteomic approaches to dissect platelet function: Half the story. Blood (2006) 1.05
Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol (2009) 1.05
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn (2009) 1.04
World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: IV. Tissue collection, processing, and storage in endometriosis research. Fertil Steril (2014) 1.03
Immunodepletion plasma proteomics by tripleTOF 5600 and Orbitrap elite/LTQ-Orbitrap Velos/Q exactive mass spectrometers. J Proteome Res (2013) 1.01
High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One (2011) 0.99
World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research. Fertil Steril (2014) 0.98
The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines. PLoS One (2012) 0.98
Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med Genomics (2009) 0.97
Mass spectrometry-based proteomics of endoscopically collected pancreatic fluid in chronic pancreatitis research. Proteomics Clin Appl (2011) 0.96
Optimizing a proteomics platform for urine biomarker discovery. Mol Cell Proteomics (2010) 0.96
Optimized sample preparation of endoscopic collected pancreatic fluid for SDS-PAGE analysis. Electrophoresis (2010) 0.95
High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays. Methods Mol Biol (2011) 0.95
Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics. Genes Nutr (2009) 0.94
Global stability of plasma proteomes for mass spectrometry-based analyses. Mol Cell Proteomics (2012) 0.93
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J (2010) 0.93
Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. J Transl Med (2014) 0.93
A method for improving SELDI-TOF mass spectrometry data quality. Proteome Sci (2007) 0.92
OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage (2015) 0.91
Elevated plasma albumin and apolipoprotein A-I oxidation under suboptimal specimen storage conditions. Mol Cell Proteomics (2014) 0.88
Systematic comparison of fractionation methods for in-depth analysis of plasma proteomes. J Proteome Res (2012) 0.88
An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn (2014) 0.87
Novel serum and urine markers for pediatric appendicitis. Acad Emerg Med (2012) 0.87
Plasma biomarker discovery using 3D protein profiling coupled with label-free quantitation. Methods Mol Biol (2011) 0.86
Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens. Biomark Med (2014) 0.86
Transferrin coated nanoparticles: study of the bionano interface in human plasma. PLoS One (2012) 0.86
Biobanking and international interoperability: samples. Hum Genet (2011) 0.85
Mass spectrometry-based proteomics for translational research: a technical overview. Yale J Biol Med (2012) 0.85
Pre-analytical stability of the plasma proteomes based on the storage temperature. Proteome Sci (2013) 0.84
Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery. J Proteomics (2010) 0.84
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol (2009) 0.83
Plasma and cerebrospinal proteomes from children with cerebral malaria differ from those of children with other encephalopathies. J Infect Dis (2013) 0.83
Application of mass spectrometry-based proteomics for biomarker discovery in neurological disorders. Ann Indian Acad Neurol (2009) 0.82
In-depth analysis of a plasma or serum proteome using a 4D protein profiling method. Methods Mol Biol (2011) 0.82
Biomarker analysis of stored blood products: emphasis on pre-analytical issues. Int J Mol Sci (2010) 0.82
The potential role of ORM2 in the development of colorectal cancer. PLoS One (2012) 0.82
Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled. World J Gastroenterol (2014) 0.81
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer (2008) 0.80
Classification-based comparison of pre-processing methods for interpretation of mass spectrometry generated clinical datasets. Proteome Sci (2009) 0.80
Degradation and Stabilization of Peptide Hormones in Human Blood Specimens. PLoS One (2015) 0.80
Cardiovascular proteomics: implications for clinical applications. Clin Lab Med (2009) 0.79
Prioritization of biomarker targets in human umbilical cord blood: identification of proteins in infant blood serving as validated biomarkers in adults. Environ Health Perspect (2012) 0.79
The proteomics big challenge for biomarkers and new drug-targets discovery. Int J Mol Sci (2012) 0.79
Interlaboratory studies and initiatives developing standards for proteomics. Proteomics (2013) 0.79
Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers. Clin Proteomics (2010) 0.79
Plasma proteomic profile of sulfur mustard exposed lung diseases patients using 2-dimensional gel electrophoresis. Clin Proteomics (2011) 0.78
Feature detection techniques for preprocessing proteomic data. Int J Biomed Imaging (2010) 0.78
Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer (2017) 0.78
Highly efficient human serum filtration with water-soluble nanoporous nanoparticles. Int J Nanomedicine (2010) 0.77
Relative quantification of several plasma proteins during liver transplantation surgery. J Biomed Biotechnol (2011) 0.77
Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers. Clin Transl Med (2016) 0.77
Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol (2013) 0.77
Data management and data integration in the HUPO plasma proteome project. Methods Mol Biol (2011) 0.77
Mass Spectrometry-based Proteomics and Peptidomics for Systems Biology and Biomarker Discovery. Front Biol (Beijing) (2012) 0.77
Analysis of endoscopic pancreatic function test (ePFT)-collected pancreatic fluid proteins precipitated via ultracentrifugation. JOP (2013) 0.77
Differential analysis of N-glycoproteome between hepatocellular carcinoma and normal human liver tissues by combination of multiple protease digestion and solid phase based labeling. Clin Proteomics (2014) 0.76
In situ characterization of nanoparticle biomolecular interactions in complex biological media by flow cytometry. Nat Commun (2016) 0.76
A proteomic approach to obesity and type 2 diabetes. J Cell Mol Med (2015) 0.76
Mesoporous silica chip: enabled peptide profiling as an effective platform for controlling bio-sample quality and optimizing handling procedure. Clin Proteomics (2016) 0.75
A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research. Front Oncol (2017) 0.75
Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling. PLoS One (2013) 0.75
Comprehensive analysis of the N and C terminus of endogenous serum peptides reveals a highly conserved cleavage site pattern derived from proteolytic enzymes. Protein Cell (2012) 0.75
Identification of ganglioside GM2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes. Cancer Sci (2016) 0.75
Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example. Proteomics Clin Appl (2014) 0.75
Serum proteomic analysis reveals high frequency of haptoglobin deficiency and elevated thyroxine level in heroin addicts. PLoS One (2014) 0.75
Proteomic Profiling of Serial Prediagnostic Serum Samples for Early Detection of Colon Cancer in the U.S. Military. Cancer Epidemiol Biomarkers Prev (2016) 0.75
α-Mangostin Extraction from the Native Mangosteen (Garcinia mangostana L.) and the Binding Mechanisms of α-Mangostin to HSA or TRF. PLoS One (2016) 0.75
Evaluating the effects of preanalytical variables on the stability of the human plasma proteome. Anal Biochem (2015) 0.75
Proteomic Workflows for Biomarker Identification Using Mass Spectrometry - Technical and Statistical Considerations during Initial Discovery. Proteomes (2013) 0.75
An automated plasma protein fractionation design: high-throughput perspectives for proteomic analysis. BMC Res Notes (2012) 0.75
In-Depth, Reproducible Analysis of Human Plasma Using IgY 14 and SuperMix Immunodepletion. Methods Mol Biol (2017) 0.75
Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. Science (2013) 6.43
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem (2002) 4.42
Forced unfolding of proteins within cells. Science (2007) 3.95
Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating. J Cell Sci (2008) 3.86
The proteome of the mouse photoreceptor sensory cilium complex. Mol Cell Proteomics (2007) 3.53
Investigations on DNA intercalation and surface binding by SYBR Green I, its structure determination and methodological implications. Nucleic Acids Res (2004) 3.45
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol (2006) 2.66
The catalytic mechanism of the ESA1 histone acetyltransferase involves a self-acetylated intermediate. Nat Struct Biol (2002) 2.56
A chromatin remodelling complex that loads cohesin onto human chromosomes. Nature (2002) 2.53
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques (2002) 2.25
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther (2005) 2.20
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (2005) 2.13
Structural and functional effects of hereditary hemolytic anemia-associated point mutations in the alpha spectrin tetramer site. Blood (2008) 2.12
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods (2007) 2.06
Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics (2005) 2.02
Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res (2006) 1.93
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell (2011) 1.86
Epigenetic regulation of condensin-mediated genome organization during the cell cycle and upon DNA damage through histone H3 lysine 56 acetylation. Mol Cell (2012) 1.85
Proteomics: a new diagnostic frontier. Clin Chem (2006) 1.82
Isolation of human NURF: a regulator of Engrailed gene expression. EMBO J (2003) 1.80
The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics (2009) 1.77
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med (2002) 1.72
Cooperativity in forced unfolding of tandem spectrin repeats. Biophys J (2003) 1.70
Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics (2003) 1.68
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes. J Biol Chem (2002) 1.67
Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res (2004) 1.63
A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics (2005) 1.62
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Cdc13 OB2 dimerization required for productive Stn1 binding and efficient telomere maintenance. Structure (2012) 1.56
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res (2005) 1.55
Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg (2003) 1.54
Retracted Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res (2008) 1.51
Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res (2004) 1.50
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Pathway shifts and thermal softening in temperature-coupled forced unfolding of spectrin domains. Biophys J (2003) 1.46
Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem (2006) 1.45
Standardization of two immunoassays for human glandular kallikrein 2. Clin Chem (2003) 1.45
A motif-based analysis of glycan array data to determine the specificities of glycan-binding proteins. Glycobiology (2009) 1.44
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
The common hereditary elliptocytosis-associated α-spectrin L260P mutation perturbs erythrocyte membranes by stabilizing spectrin in the closed dimer conformation. Blood (2013) 1.43
Quantification of coagulation factor XIII activity by a thio-NADH based assay using factor XIII immuno-depleted plasma as a diluent for calibration. Clin Chem Lab Med (2010) 1.39
Two-color, rolling-circle amplification on antibody microarrays for sensitive, multiplexed serum-protein measurements. Genome Biol (2004) 1.39
Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics (2005) 1.38
Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics (2011) 1.36
Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer (2005) 1.35
Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems. PLoS One (2010) 1.34
Mitogen-activated protein kinase-mediated phosphorylation of peroxiredoxin 6 regulates its phospholipase A(2) activity. Biochem J (2009) 1.32
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem (2008) 1.31
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol (2003) 1.30
Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res (2009) 1.30
Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun (2013) 1.29
MYST protein acetyltransferase activity requires active site lysine autoacetylation. EMBO J (2011) 1.29
Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell (2012) 1.28
Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer (2005) 1.28
Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila) (2009) 1.27
High-density single-nucleotide polymorphism maps of the human genome. Genomics (2005) 1.27
Endoplasmic reticulum PI(3)P lipid binding targets malaria proteins to the host cell. Cell (2012) 1.26
Erythrocyte detergent-resistant membrane proteins: their characterization and selective uptake during malarial infection. Blood (2003) 1.26
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
Comparison of extensive protein fractionation and repetitive LC-MS/MS analyses on depth of analysis for complex proteomes. J Proteome Res (2010) 1.25
The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev (2010) 1.25
Pathogenic proline mutation in the linker between spectrin repeats: disease caused by spectrin unfolding. Blood (2006) 1.22
Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer. Mol Oncol (2007) 1.21
Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res (2003) 1.20
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther (2004) 1.20
Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res (2004) 1.19
Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics (2005) 1.18
Dematin and adducin provide a novel link between the spectrin cytoskeleton and human erythrocyte membrane by directly interacting with glucose transporter-1. J Biol Chem (2008) 1.18
Profiling bladder cancer using targeted antibody arrays. Am J Pathol (2006) 1.17
Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res (2007) 1.17
Mass spectrometric and computational analysis of cytokine-induced alterations in the astrocyte secretome. Proteomics (2009) 1.17
Structural basis for dimerization in DNA recognition by Gal4. Structure (2008) 1.16
Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem (2010) 1.16
Anticancer activities of Oldenlandia diffusa. J Herb Pharmacother (2004) 1.16
Biomarkers in prostate cancer: what's new? Curr Opin Oncol (2014) 1.16
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. Anal Chem (2011) 1.15
A functional annotation of subproteomes in human plasma. Proteomics (2005) 1.15
Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. EMBO J (2013) 1.14
Systematic discovery of ectopic pregnancy serum biomarkers using 3-D protein profiling coupled with label-free quantitation. J Proteome Res (2011) 1.14